Surface markers expressed by B lymphocytes are all potential therapeutic targets for the treatment of autoimmune neurological diseases, such as CD20, CD19, B-cell activating factor (BAFF) receptor (interacting with the Blyss protein), transmembrane activator and CAML interactor (TACI, interacting with the protein—a proliferation-inducing ligand—APRIL), and CD22. The gene discussed is TNFRSF13B; the disease is autoimmune disorder of the nervous system.